Author/Authors :
Jafarian, Amir Hossein Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Mirshekar Nasirabadi, Khatoone Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Etemad, Sare Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Jafaripour, Masoumeh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Darijani, Mansoore Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Sheikhi, Maryam Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Ayatollahi, Hossein Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Shakeri, Sepideh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Shams, Fatemeh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Davari, Saeed Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran
Abstract :
BRAF mutations were studied in various populations for
prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to
KRAS. Oncogenic activating of BRAF mutations were studied lately in almost 0%-
10% of prostate cancer cases.
Methods: In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded
samples of prostate adenocarcinoma. A hundred archived samples of adjacent
benign prostatic hyperplasia were chosen as normal control. This study was done in
pathology laboratory of Qaem Hospital during 2013-2015.
Results: Total number of 200 PC and normal cases was investigated for BRAF
V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was
not detected in normal cases. There were no significant differences between patient
and control groups for this mutation (P>0.99). The frequency of BRAF V600E mutation
was not significant in different age groups (P>0.285); the most frequency was
related to the age range of 71-80. No significant difference was observed between
tumor grade and BRAF mutation (P=0.21).
Conclusion: According to our findings, BRAF gene mutations did not play essential
role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target
for therapy.